drugset / Trial / NCT02657252

Polidocanol Versus Glucose Treatment of Telangiectasia Trial

NCT02657252

RandomizedParallel-groupQuadruple-blindTreatment

Summary

It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.

Timeline

Start
2015-01
Primary completion
2016-09
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glucose Unknown 70 %
Comparator Glucose Unknown 75 %
Comparator Polidocanol Other / unclassified 0.2 %